Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.

Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen's stock plummeted to its lowest point in a year, experiencing a dramatic 10% drop to $264.59 in early trading following the release of disappointing results from its Maritide obesity treatment ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...